CCM
BEAM icon

Cribstone Capital Management’s Beam Therapeutics BEAM Stock Holding History

Cribstone Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9
Closed – – 419
2022
Q3 		$0 Hold
9
– – ﹤0.01% 421
2022
Q2 		$0 Hold
9
– – ﹤0.01% 465
2022
Q1 		$1K Hold
9
– – ﹤0.01% 368
2021
Q4 		$1K Hold
9
– – ﹤0.01% 360
2021
Q3 		$1K Sell
9
-200
-96% -$20.1K ﹤0.01% 351
2021
Q2 		$27K Hold
209
– – 0.02% 189
2021
Q1 		$17K Buy
+209
New +$19.9K 0.01% 207

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cribstone Capital Management's BEAM Position: Q4 2022 in Review

Cribstone Capital Management sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 9 shares.

Cribstone Capital Management first reported a position in BEAM in Q1 2021 and held it in 7 quarters. The position peaked at $27K in Q2 2021. 209 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • Cribstone Capital Management reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cribstone Capital Management sold 9 Beam Therapeutics shares in Q4 2022.
  • Cribstone Capital Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 7 quarters.
  • Cribstone Capital Management's Beam Therapeutics position peaked at $27K in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on Cribstone Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.